This approach helps maintain effectiveness and allows assessment of whether benefits persist when off the peptide
Receive the latest news and breaking updates, straight from our newsroom to your inbox.
What FDA has said recently (high-level, patient-friendly summary) FDA maintains a page describing certain bulk drug substances used in compounding that may present significant safety risks, including AOD-9604, noting concerns such as potential immunogenicity and limited safety-related information for some uses/routes
This too: Health Canada issued a public advisory in January warning that fake or unauthorised GLP-1 alternatives carry risks ranging from infections to contamination with solvents, heavy metals, and microbials and that some vendors misuse Health Canada logos to mislead consumers
About this article Cite this article Katrevula, A., Kalapala, R., Agrawal, S